Back to search

Poland· PL-100453057

Fingolimod Fresenius Kabi

A fingolimod product containing fingolimodum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 3 of our 19 countries.

ATC L04AA27

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedFingolimod Fresenius KabiATCL04AA27REGISTER NO.PL-100453057PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Fingolimod is registered in 3 of 19 countries.

Countries holding a registration under ATC L04AA27 (fingolimod), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Fingolimod · ATC L04AA27

3 / 19 countries

  • Belgiumprice
  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Fingolimodum
Manufacturer
Accord Healthcare Polska Sp. z o.o.
Country
Poland (PL)
ATC code
L04AA27
ATC class
Fingolimod
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991484200
  • gtin
    05909991484217
  • gtin
    05909991484224

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

584 interactions on record for fingolimod.

Graded by severity as the source publishes them — 503 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fingolimod · interactions on record

584 records

  • 503 severe
  • 77 moderate
  • 4 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fingolimod in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fingolimod products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Areleptan, Chantico
  • Belgium · Fingolimod Ab, Fingolimod Eg
  • Bulgaria · Chantico, Inzolfi
  • Cyprus · Fingolimod Adelco, Fingolimod Remedica
  • Czechia · Areleptan, Bonaxon
  • Germany · Fingod, Fingolimod 123 Acurae Pharma
  • Denmark · Areleptan, Bonaxon
  • Estonia · Chantico, Efigalo
  • Spain · Fingolimod, Fingolimod Aurovitas
  • Finland · Fingolimod, Fingolimod Avansor
  • France · Fingolimod Arrow, Fingolimod Benta
  • United Kingdom (Northern Ireland) · Fingolimod, Fingolimod Amarox
  • Greece · Fingolimod Adelco, Fingolimod Medochemie
  • Croatia · Areleptan, Arlesias
  • Hungary · Bonaxon, Chantico
  • Ireland · Fingolimod Clonmel, Fingolimod Flynn Pharma
  • Iceland · Fingolimod, Fingolimod Accord
  • Italy · Fingolimod Aurobindo, Fingolimod Dr. Reddy’s
  • Liechtenstein · Fingolimod Accord, Fingolimod Mylan
  • Lithuania · Chantico, Efigalo
  • Luxembourg · Fingolimod Eg, Fingolimod Ratiopharm
  • Latvia · Bonaxon, Chantico
  • Malta · Fingolimod Denk, Fingolimod Remedica
  • Netherlands · Chantico, Fenoxa
  • Norway · Areleptan, Fingolimod Accord
  • Portugal · Bluesar, Fingolimod Bluefish
  • Romania · Fingolimod Dr. Reddys, Fingolimod Msn
  • Sweden · Areleptan, Fingolimod Amarox
  • Slovenia · Areleptan, Arlesias
  • Slovakia · Areleptan, Bonaxon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dbea074c-c8d0-43d2-adf5-2a91f7ebe349
GET /v1/drugs/dbea074c-c8d0-43d2-adf5-2a91f7ebe349?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "0,5 mg",
  "packaging": "05909991484200 ¦ Rpz ¦ 145136\n28 kaps.\n05909991484217 ¦ Rpz ¦ 145137\n98 kaps.\n05909991484224 ¦ Rpz ¦ 145138\n7 kaps.",
  "substance": "Fingolimodi hydrochloridum 0.56 mg",
  "common_name": "Fingolimodum",
  "pl_product_id": "100453057",
  "pozwolenie_nr": "27089",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}

See everything about fingolimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.